香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 與FBD就HCB101訂立許可協議 上海復宏漢霖生物技術股份有限公司（「本公司」）董事會欣然宣佈，於二零二 五年六月三十日，本公司與FBD Biologics Limited（「FBD」）訂立一份許可協 議（「許可協議」），據此，FBD同意授予本公司一項獨家許可，以於領域（定 義如下）及於本公司許可區域（定義如下）內開發、生產、商業化或以其他方 式利用HCB101（「許可分子」）和以其作為原料藥的藥品（「許可產品」）。 B. 許可協議中的主要條款 許可授予 FBD將授予本公司一項獨家許可，供本公司基於其專有 技術和專利及使用FBD監管文件在領域內及本公司許可 區域內開發、生產、商業化或以其他方式利用許可分子 和許可產品。 FBD將保留 ...

Group 1 - The core viewpoint is that Fuhong Hanlin (02696) has seen a significant stock price increase of over 6% following the announcement of a stock option plan and restricted share unit plan, which requires shareholder approval [1] - The board of directors approved the conditional grant of a total of 6.985 million stock options and 698.5 restricted share units to 279 participants, including 75,000 stock options and restricted share units to CEO Dr. Zhu Jun [1] - Fuhong Hanlin's PD-L1 ADC (HLX43) has entered the international multi-center Phase II clinical study for advanced non-small cell lung cancer patients, marking it as the first PD-L1 ADC to enter Phase II clinical trials globally [1] Group 2 - CMB International highlights Fuhong Hanlin's potential to evolve from a profitable biosimilar company to a leading player in the biopharmaceutical sector, with promising clinical data for several innovative drugs including HLX43 and Serplulimab [2] - The target price for Fuhong Hanlin has been raised from HKD 20.33 to HKD 61.98, maintaining a "Buy" rating due to the company's strong commercial performance of its products and ongoing FDA reviews for HLX14 and HLX11 [2] - The company is actively expanding its global biosimilar business through partnerships with pharmaceutical companies, which is expected to enhance overseas revenue sources [2]

Core Viewpoint - The company, a leading domestic biotechnology firm focused on research and development, has successfully launched six products in China and four products in international markets, with a strong pipeline in oncology and autoimmune diseases [1][4]. Product Pipeline - The company has six products approved for the domestic market, including four biosimilars and one innovative product [1]. - HLX43 is the first PD-L1 ADC to enter Phase II clinical trials globally, with promising efficacy and safety data reported at the 2025 ASCO annual meeting [2]. - HLX22, a novel anti-HER2 monoclonal antibody, shows potential to change the standard treatment for HER2-positive gastric cancer, with ongoing Phase III trials [3]. - The company’s product Hanshu (sruvulimab) has multiple approved indications and is the first PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) [3]. International Market Expansion - The company has successfully launched four products in international markets, including Hanquyou and Hanlikang, across multiple countries [3]. - The company has established partnerships for global sales of its biosimilars, enhancing its international presence [3]. Financial Projections - Revenue projections for the company are estimated at 5.96 billion, 6.36 billion, and 7.02 billion yuan for 2025-2027, with net profits expected to reach 790 million, 900 million, and 1.14 billion yuan respectively [4]. - The target price for the company is set at 71.0 HKD, indicating a potential upside of 40% [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 78.01 HKD per share, indicating an expected return of over 20% within the next six months [4]. Core Insights - The company has approved a stock option plan and a restricted share unit plan, which will be subject to shareholder approval. A total of 6.985 million stock options and restricted share units have been conditionally granted to 279 participants, including 75,000 each to the CEO [1][2]. - The HLX43 PD-L1 ADC has completed dosing in an international Phase II clinical trial, marking it as the first PD-L1 ADC to enter this stage globally. Initial Phase I data showed promising safety and efficacy results in patients with advanced non-small cell lung cancer [3]. Financial Projections - The company is projected to achieve total revenues of 5.873 billion, 5.970 billion, and 7.125 billion HKD for the years 2025, 2026, and 2027, representing year-on-year growth rates of 2.60%, 1.64%, and 19.36% respectively. Net profits attributable to shareholders are expected to be 827 million, 797 million, and 1.122 billion HKD for the same years [4].

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. plans to adopt an equity incentive program for its subsidiary, WuXi Biologics, which includes a stock option plan and a restricted stock unit plan aimed at attracting and retaining skilled personnel [2][7][30]. Group 1: Overview of the Equity Incentive Plan - The equity incentive plan consists of two independent programs: (1) a stock option plan and (2) a restricted stock unit plan [2][7]. - The total number of stock options and restricted stock units to be granted under these plans will not exceed 8% of WuXi Biologics' total shares (excluding treasury shares) as of the adoption date [3][8]. - As of the announcement date, WuXi Biologics has a total of 543,494,853 shares, with the group holding 63.43% of the shares [3][28]. Group 2: Initial Grant Details - The initial grant will involve issuing a total of 6.985 million stock options and 6.985 million restricted stock units to 279 qualified individuals, with an exercise price of HKD 50.25 per share for stock options and a vesting price of RMB 1 per restricted stock unit [3][24][25]. - The initial grant is subject to approval by WuXi Biologics' shareholders and will not constitute a related party transaction [4][10][27]. Group 3: Purpose and Conditions of the Plan - The purpose of the equity incentive plan is to attract, motivate, and retain skilled personnel, recognizing their contributions and encouraging them to enhance the value of WuXi Biologics [11][30]. - The plan's effectiveness requires approval from WuXi Biologics' shareholders and compliance with the Hong Kong Stock Exchange's listing rules [13][32]. Group 4: Financial Overview of WuXi Biologics - WuXi Biologics, established in February 2010 and listed on the Hong Kong Stock Exchange in September 2019, focuses on the research, production, and sales of monoclonal antibody drugs [28]. - As of December 31, 2024, WuXi Biologics reported total assets of RMB 1,059.75 million, total liabilities of RMB 758.39 million, and a net profit of RMB 82.05 million [29].

Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 建議採納購股權計劃及受限制股份單位計劃 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 及 根據購股權計劃及受限制股份單位計劃分別有條件授出 購股權及受限制股份單位 建議採納購股權計劃及受限制股份單位計劃 於2025年6月27日，董事會決議批准建議採納購股權計劃及受限制股份單位計 劃，須經股東批准。該兩項計劃均構成上市規則第十七章項下的股份計劃，因 此將須遵守上市規則第十七章的規定。 根據購股權計劃及受限制股份單位計劃分別有條件授出購股權及受限制股 份單位 於2025年6月27日，董事會決議根據購股權計劃及受限制股份單位計劃分別向 279名參與者作出合共6,985,000份購股權及6,985,000份受限制股份單位的首次 授予。首次授予購股權及首次授予受限制股份單位分別須待採納購股權計劃及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 董事名單與其角色及職能 董事名單與其角色及職能 董事會（「董事會」）成員載列如下： 董事會主席 Wenjie Zhang先生 （非執行董事） 執行董事 朱俊博士 （首席執行官） 獨立非執行董事 蘇德揚先生 陳力元博士 趙國屏博士 宋瑞霖博士 1 附註： C 委員會主席 非執行董事 陳啟宇先生 吳以芳先生 關曉暉女士 文德鏞先生 Xingli Wang博士 M 委員會成員 代表董事會 上海復宏漢霖生物技術股份有限公司 主席 Wenjie Zhang 香港，二零二五年六月二十七日 於本公告日期，本公司董事會包括主席及非執行董事Wenjie Zhang先生，執行董 事朱俊博士，非執行董事陳啟宇先生、吳以芳先生、關曉暉女士、文德鏞先生及 Xingli ...

提名委員會職權範圍 提名委員會 職權範圍 定義 1. 在本職權範圍（ 職權範圍 ）內： 公司章程 指本公司的公司章程； 董事會 指本公司的董事會； 本公司 指上海復宏漢霖生物技術股份有限公司； 公司秘書 指本公司的公司秘書； 董事 指董事會的成員； 於二零一九年九月二日採納 （於二零二五年六月二十七日修訂） 上海復宏漢霖生物技術股份有限公司 股東大會 指本公司股東的股東大會； 本集團 指本公司及其附屬公司； 提名委員會 指按董事會決議根據本職權範圍設立的提名委員會； 股東 指本公司不時的股東；及 聯交所 指香港聯合交易所有限公司。 設立 2. 提名委員會於二零一九年九月二日由董事會決議設立。 成員 1 授權 職責 2 8. 會議應於適當時召開，但每年不得少於一次。 9. 會議議程及其他相關文件應於提名委員會會議的預定日期至少三天前（或其 他由委員會成員同意的期限）全部及時發送至所有成員。 10. 提名委員會會議可遵循按公司章程的相關條款（經不時修訂）設定的董事會會 議程式。 12. 提名委員會獲董事會授權在本職權範圍規定的範圍內開展活動。其有權要求 任何僱員提供其所需的任何資料，且所有僱員被指示與提名委員會合 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 建議修訂公司章程 建議修訂相關議事規則 建議修訂其他企業管治措施 及 委任提名委員會委員 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則（「上市規則」）第13.51條的規定作出。 建議修訂公司章程 經考慮（其中包括）有關適用法律法規的更新，為符合最新的法律及監管要求以及 結合本公司實際情況，建議對本公司現有公司章程（「公司章程」）中的相關內容作 出修訂（「公司章程的建議修訂」），修訂詳情將載列於其後適時向本公司股東（「股 東」）發出的一份股東大會通函（「通函」）。 公司章程的建議修訂須待股東於股東大會上以特別決議案批准後方告作實，並自 此生效。 公司章程的建議修訂須向中國有關機關備案及登記。本公司 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [8][10]. Core Views - The company has a strong product pipeline with potential first-in-class (FIC) candidates, including HLX43 (PD-L1 ADC) and HLX22 (HER2 monoclonal antibody) [4][5][34]. - The company is expected to achieve significant revenue growth, with projected revenues of CNY 59.6 billion, CNY 63.6 billion, and CNY 70.2 billion from 2025 to 2027 [8][16]. - The target price is set at HKD 71.0, indicating a potential upside of 40% [8][14]. Summary by Sections Product Pipeline - The company has six products approved in China, including Hanshu (HLX10), four biosimilars, and one in-licensed product [4][25]. - HLX43 is the first PD-L1 ADC to enter Phase II clinical trials globally, with promising efficacy and safety data reported at the ASCO 2025 conference [4][39]. - HLX22 is expected to change the first-line treatment standard for HER2-positive gastric cancer, with ongoing Phase III trials [5]. Financial Projections - Revenue projections for 2025-2027 are CNY 59.6 billion, CNY 63.6 billion, and CNY 70.2 billion, with biosimilar sales contributing CNY 51.7 billion, CNY 55.7 billion, and CNY 58.1 billion respectively [9][16]. - The company is expected to achieve net profits of CNY 7.9 billion, CNY 9.0 billion, and CNY 11.4 billion during the same period [9][16]. Market Expansion - The company has successfully launched four products in international markets, including Hanshu in over 30 countries [7][25]. - The company has established multiple commercial partnerships for its biosimilars, enhancing its international market presence [30][31]. Clinical Development - The company is actively conducting multiple Phase II and III clinical trials for its innovative drugs, with HLX43 and HLX22 being key candidates [4][5][34]. - The company has a robust pipeline with over 10 innovative drugs and 10 biosimilars under development [26][28].